The historical rank and industry rank for Cowealth Medical China Co's ROE % or its related term are showing as below:
SHSE:603122'
s ROE % Range Over the Past 10 Years
Min: -3.28 Med: 9.63 Max: 17.1
Current: -3.28
During the past 9 years, Cowealth Medical China Co's highest ROE % was 17.10%. The lowest was -3.28%. And the median was 9.63%.
SHSE:603122's ROE % is ranked worse than 54.95% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.31
vs SHSE:603122: -3.28
Cowealth Medical China Co (SHSE:603122) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Cowealth Medical China Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cowealth Medical China Co ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cowealth Medical China Co's ROE % distribution charts can be found below:
* The bar in red indicates where Cowealth Medical China Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Cowealth Medical China Co (SHSE:603122) has a ROE % of -3.15% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Cowealth Medical China Co and its competitors. According to the industry distribution chart, Cowealth Medical China Co ranks #111 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 55%.
Is Cowealth Medical China Co's ROE % too high?
Cowealth Medical China Co's current ROE % is -3.15%. Based on the distribution chart, Cowealth Medical China Co ranks #111 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Cowealth Medical China Co has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cowealth Medical China Co's ROE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cowealth Medical China Co ranks #111 out of 202 companies for ROE %. This places Cowealth Medical China Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Cowealth Medical China Co and its competitors. Cowealth Medical China Co's current ROE % is -3.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cowealth Medical China Co stock overvalued right now?
Based on GuruFocus' analysis, Cowealth Medical China Co (SHSE:603122) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.88, compared to a current price of ¥11.48 — trading 195.9% above its estimated fair value. The current ROE % is -3.15%. Cowealth Medical China Co's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Cowealth Medical China Co (SHSE:603122), the current ROE % is -3.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cowealth Medical China Co (SHSE:603122) Overvalued in 2026?
Based on GuruFocus' analysis, Cowealth Medical China Co stock appears to be overvalued.
The current stock price of ¥11.48 is trading 195.9% above its estimated GF Value™ of ¥3.88.
GuruFocus considers Cowealth Medical China Co to be Significantly Overvalued.
Key valuation signals for SHSE:603122:
ROE %: -3.15%
GF Value™: ¥3.88 vs. price of ¥11.48 (195.9% above fair value)
No single metric tells the full story. See the SHSE:603122 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603122 has been successfully added to your 
